vs
Side-by-side financial comparison of MAINZ BIOMED N.V. (MYNZ) and Sanofi (SNY). Click either name above to swap in a different company.
Mainz Biomed N.V. is a molecular diagnostics company specializing in the development and commercialization of non-invasive early detection tests for gastrointestinal cancers, primarily colorectal cancer. Its flagship product ColoAlert is approved and available across European markets, with active expansion initiatives targeting North America and other global regions.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of th...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 23 | $214.8K | — | ||
| Q3 23 | $181.7K | — | ||
| Q2 23 | $248.9K | — | ||
| Q1 23 | $1 | — | ||
| Q3 22 | $96.8K | — | ||
| Q2 22 | $139.2K | — |
| Q4 23 | — | — | ||
| Q3 23 | $-6.3M | — | ||
| Q2 23 | $-8.3M | — | ||
| Q1 23 | $-6.6M | — | ||
| Q3 22 | $-5.6M | — | ||
| Q2 22 | $-6.9M | — |
| Q4 23 | 62.7% | — | ||
| Q3 23 | 48.0% | — | ||
| Q2 23 | 59.8% | — | ||
| Q1 23 | — | — | ||
| Q3 22 | 19.2% | — | ||
| Q2 22 | 58.0% | — |
| Q4 23 | — | — | ||
| Q3 23 | -3104.9% | — | ||
| Q2 23 | -3183.9% | — | ||
| Q1 23 | -648755600.0% | — | ||
| Q3 22 | -5657.1% | — | ||
| Q2 22 | -4989.9% | — |
| Q4 23 | — | — | ||
| Q3 23 | -3467.7% | — | ||
| Q2 23 | -3314.7% | — | ||
| Q1 23 | -656091600.0% | — | ||
| Q3 22 | -5781.8% | — | ||
| Q2 22 | -4983.3% | — |
| Q4 23 | — | — | ||
| Q3 23 | $-0.39 | — | ||
| Q2 23 | $-0.56 | — | ||
| Q1 23 | $-0.45 | — | ||
| Q3 22 | $-0.39 | — | ||
| Q2 22 | $-0.48 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
